Michael Hojby Rasmussen
Overview
Explore the profile of Michael Hojby Rasmussen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
583
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Otsuka F, Rasmussen M, Endo T, Svaerke C, Tahara S, Johannsson G
Front Endocrinol (Lausanne)
. 2025 Feb;
16:1534891.
PMID: 39991735
Introduction: Somapacitan is a long-acting growth hormone (GH) derivative approved for once-weekly treatment of adult GH deficiency (AGHD). This study aimed to evaluate the efficacy and safety of somapacitan and...
2.
Dombernowsky S, Damholt B, Rasmussen M, Svaerke C, Kildemoes R
Clin Pharmacokinet
. 2024 Jul;
63(7):1015-1024.
PMID: 38969919
Study Design And Objective: Randomised, double-blind, crossover trial to confirm bioequivalence of somapacitan, a long-acting growth hormone (GH), in 5 mg/1.5 mL and 10 mg/1.5 mL strengths in equimolar doses....
3.
Mori J, Ohata Y, Fujisawa Y, Sato Y, Rohrich S, Rasmussen M, et al.
Clin Endocrinol (Oxf)
. 2024 Feb;
100(4):389-398.
PMID: 38368603
Objective: Somapacitan is a long-acting growth hormone (GH) derivative developed for the treatment of GH deficiency (GHD). This study evaluates the efficacy and tolerability of somapacitan in Japanese children with...
4.
Miller B, Blair J, Rasmussen M, Maniatis A, Mori J, Bottcher V, et al.
J Clin Endocrinol Metab
. 2023 Jul;
108(12):3090-3099.
PMID: 37406251
Context: Somapacitan is a long-acting GH derivative for treatment of GH deficiency (GHD). Objective: Evaluate the efficacy and tolerability of somapacitan in children with GHD after 2 years of treatment...
5.
Savendahl L, Battelino T, Rasmussen M, Brod M, Rohrich S, Saenger P, et al.
J Clin Endocrinol Metab
. 2023 Mar;
108(10):2569-2578.
PMID: 36995872
Context: Growth hormone deficiency (GHD) in children is currently treated with daily injections of GH, which can be burdensome for patients and their parents/guardians. Somapacitan is a GH derivative in...
6.
Miller B, Blair J, Rasmussen M, Maniatis A, Kildemoes R, Mori J, et al.
J Clin Endocrinol Metab
. 2023 Mar;
108(8):e647-e648.
PMID: 36869702
No abstract available.
7.
Takahashi Y, Biller B, Fukuoka H, Ho K, Rasmussen M, Nedjatian N, et al.
Pituitary
. 2022 Nov;
26(1):57-72.
PMID: 36380045
Purpose: The long-term effects of long-acting growth hormone (LAGH) analogues on glucose metabolism in adult growth hormone deficiency (AGHD) are not known. We investigated the impact of LAGH somapacitan, administered...
8.
Brod M, Rasmussen M, Alolga S, Beck J, Bushnell D, Lee K, et al.
Pharmacoecon Open
. 2022 Oct;
7(1):121-138.
PMID: 36255609
Purpose: The aim was to evaluate the measurement properties of the Growth Hormone Deficiency-Child Treatment Burden Measure-Child (GHD-CTB-Child), a patient-reported outcome (PRO) for children aged 9 to < 13 years;...
9.
Miller B, Blair J, Rasmussen M, Maniatis A, Kildemoes R, Mori J, et al.
J Clin Endocrinol Metab
. 2022 Sep;
107(12):3378-3388.
PMID: 36062966
Context: Somapacitan, a once-weekly reversible albumin-binding GH derivative, is evaluated in children with GH deficiency (GHD). Objective: To demonstrate efficacy and safety of somapacitan vs daily GH. Methods: REAL4 is...
10.
Kildemoes R, Hollensen C, Biller B, Johannsson G, Takahashi Y, Rasmussen M
Eur J Endocrinol
. 2022 May;
187(1):27-38.
PMID: 35521713
Objective: Growth hormone (GH) replacement therapy in patients with adult growth hormone deficiency (AGHD) is individually titrated due to variable dose-responses among patients. The aim of this study was to...